

## WEST Search History

Hide Items

Restore

Clear

Cancel

DATE: Wednesday, January 10, 2007

Hide?	Set Name	Query	Hit Count
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L16	L13 and neurons	48
<input type="checkbox"/>	L15	selenoprotein p administration	1
<input type="checkbox"/>	L14	L13 and acetylcholine receptor	18
<input type="checkbox"/>	L13	selenoprotein P	145
<input type="checkbox"/>	L12	selenoprotein p and neurotransmission	7
	<i>DB=DWPI,JPAB,EPAB,USOC,USPT,PGPB; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L11	WADA-KEIJI!	310
<input type="checkbox"/>	L10	NODA-MAMI!	3
<input type="checkbox"/>	L9	MAEDA-HIROAKI!	335
<input type="checkbox"/>	L8	MATSUDA-JUNICHI!	321
<input type="checkbox"/>	L7	KAMINAKA-KAZUYOSHI!	15
<input type="checkbox"/>	L6	HIRASHIMA-MASAKI!	29
<input type="checkbox"/>	L5	HIRASHIMA-MASAKI!	29
<input type="checkbox"/>	L4	NARUSE-TAKESHI!	34
<input type="checkbox"/>	L3	NARUSE-TAKESHI!	34
<input type="checkbox"/>	L2	KAWAMURA-RYOICHI!	30
<input type="checkbox"/>	L1	KAWAMURA-RYOICHI!	30

END OF SEARCH HISTORY

Can #11 10/5 36963  
WEST (PGPB, USPT, USOC, DWPI, JPAB, EPAB)  
1/10/07  
AD

FILE 'MEDLINE' ENTERED AT 17:52:10 ON 10 JAN 2007

FILE 'BIOSIS' ENTERED AT 17:52:10 ON 10 JAN 2007

Copyright (c) 2007 The Thomson Corporation

=> s selenoprotein

L1 2252 SELENOPROTEIN

=> s neuro? disease

L2 61952 NEURO? DISEASE

=> s acetylcholine receptor

L3 32635 ACETYLCHOLINE RECEPTOR

=> s treatment

L4 3626407 TREATMENT

=> s l2 and l4

L5 10537 L2 AND L4

=> s l5 and l3

L6 99 L5 AND L3

=> s l6 and l1

L7 0 L6 AND L1

=> s l2 and l1

L8 11 L2 AND L1

=> s neurotransmission

L9 29905 NEUROTRANSMISSION

=> s l1 and l9

L10 0 L1 AND L9

=> disp l8 ibib abs 1-11

Can # 10/536 963.  
STN (BIOSIS, MEDLINE)  
1/10/07  
AG

FILE 'CAPLUS' ENTERED AT 18:03:56 ON 10 JAN 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Jan 2007 VOL 146 ISS 3  
FILE LAST UPDATED: 9 Jan 2007 (20070109/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> E KAWAMURA RYOICHI/IN 25

E1	2	KAWAMURA ROKUTARO/IN
E2	1	KAWAMURA RYO/IN
E3	14 -->	KAWAMURA RYOICHI/IN
E4	7	KAWAMURA RYOJI/IN
E5	6	KAWAMURA RYOSUKE/IN
E6	1	KAWAMURA RYOUITI/IN
E7	1	KAWAMURA RYUHJI/IN
E8	1	KAWAMURA RYUICHI/IN
E9	2	KAWAMURA RYUJI/IN
E10	9	KAWAMURA RYUSUKE/IN
E11	1	KAWAMURA RYUZO/IN
E12	1	KAWAMURA S/IN
E13	18	KAWAMURA SABURO/IN
E14	1	KAWAMURA SACHIKO/IN
E15	1	KAWAMURA SADAMI/IN
E16	23	KAWAMURA SADA0/IN
E17	1	KAWAMURA SADATO/IN
E18	1	KAWAMURA SADAYUKI/IN
E19	5	KAWAMURA SAIHEI/IN
E20	1	KAWAMURA SAKAE/IN
E21	2	KAWAMURA SARA/IN
E22	2	KAWAMURA SARARA/IN
E23	4	KAWAMURA SATOJI/IN
E24	1	KAWAMURA SATOKO/IN
E25	5	KAWAMURA SATOMI/IN

=> S (E3) AND (SELENOPROTEIN)

14 "KAWAMURA RYOICHI"/IN  
1089 SELENOPROTEIN  
626 SELENOPROTEINS  
1298 SELENOPROTEIN

(SELENOPROTEIN OR SELENOPROTEINS)

L1 2 ("KAWAMURA RYOICHI"/IN) AND (SELENOPROTEIN)

=> DIS L1 1 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS.  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L1 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:529749 CAPLUS  
 DOCUMENT NUMBER: 141:65101  
 TITLE: Selenocysteine-containing proteins and peptides as antiinflammatory agents  
 INVENTOR(S): Matsuyama, Reiko; Kawamura, Ryoichi; Sasaki, Takumi; Naruse, Takeshi; Hirashima, Masaki; Maeda, Hiroaki  
 PATENT ASSIGNEE(S): D.N.H. Chip Kenkyusho K. K., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 16 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004182683	A	20040702	JP 2002-354122	20021205
PRIORITY APPLN. INFO.:			JP 2002-354122	20021205

ABSTRACT:

Selenocysteine-containing proteins and peptides, including selenoprotein P, are claimed as antiinflammatory agents for treatment of IL-6 formation-related inflammatory diseases.

=> DIS L1 2 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS  
 DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L1 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:490735 CAPLUS  
 DOCUMENT NUMBER: 141:47351  
 TITLE: Novel agent for improving neurotransmission failure  
 INVENTOR(S): Kawamura, Ryoichi; Naruse, Takeshi; Hirashima, Masaki; Kaminaka, Kazuyoshi; Matsuda, Junichi; Maeda, Hiroaki; Noda, Mami; Wada, Keiji  
 PATENT ASSIGNEE(S): Juridical Foundation the Chemo-Sero-Therapeutic Research Institute, Japan  
 SOURCE: PCT Int. Appl., 31 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004050114	A1	20040617	WO 2003-JP15227	20031128
W: US				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
JP 2004182616	A	20040702	JP 2002-348714	20021129
EP 1566181	A1	20050824	EP 2003-812336	20031128
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK				
US 2006211609	A1	20060921	US 2005-536963	20050531
PRIORITY APPLN. INFO.:			JP 2002-348714	A 20021129
			WO 2003-JP15227	W 20031128

ABSTRACT:

It is intended to provide a novel agent for improving neurotransmission failure. In a preferable case, an agent for improving neurotransmission failure which contains, as the major active ingredient(s), a selenocysteine-containing protein typified by selenoprotein P, a

C-terminal peptide of this protein or such peptides. This agent is appropriate in improving neurotransmission failure diseases caused by various factors.

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> E NARUSE TAKESHI/IN 25

E1	1	NARUSE TAKEMITSU/IN
E2	5	NARUSE TAKEO/IN
E3	12 -->	NARUSE TAKESHI/IN
E4	4	NARUSE TAKUMI/IN
E5	1	NARUSE TAKUSANE/IN
E6	24	NARUSE TATSUYA/IN
E7	2	NARUSE TERUKAZU/IN
E8	1	NARUSE TETSUO/IN
E9	18	NARUSE TETSURO/IN
E10	1	NARUSE TETSUYA/IN
E11	1	NARUSE TOHRU/IN
E12	2	NARUSE TOKUYOSHI/IN
E13	4	NARUSE TOMISABURO/IN
E14	8	NARUSE TOMOHIRO/IN
E15	1	NARUSE TOMOYUKI/IN
E16	1	NARUSE TOORU/IN
E17	1	NARUSE TORU/IN
E18	1	NARUSE TOSHIHIKO/IN
E19	3	NARUSE TOSHIHIRO/IN
E20	7	NARUSE TOSHIMICHI/IN
E21	3	NARUSE TOSHINORI/IN
E22	3	NARUSE TOSHIO/IN
E23	1	NARUSE TSUGIO/IN
E24	1	NARUSE TSUNCHIDE/IN
E25	4	NARUSE TSUNEHIDE/IN

=> S (E3) AND (SELENOPROTEIN)

12 "NARUSE TAKESHI"/IN  
1089 SELENOPROTEIN  
626 SELENOPROTEINS  
1298 SELENOPROTEIN

(SELENOPROTEIN OR SELENOPROTEINS)

L2 6 ("NARUSE TAKESHI"/IN) AND (SELENOPROTEIN)

=> DIS L2 1 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L2 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:529749 CAPLUS

DOCUMENT NUMBER: 141:65101

TITLE: Selenocysteine-containing proteins and peptides as antiinflammatory agents

INVENTOR(S): Matsuyama, Reiko; Kawamura, Ryoichi; Sasaki, Takumi; Naruse, Takeshi; Hirashima, Masaki; Maeda, Hiroaki

PATENT ASSIGNEE(S): D.N.H. Chip Kenkyusho K. K., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 16 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

JP 2004182683                      A            20040702            JP 2002-354122                      20021205  
PRIORITY APPLN. INFO.:                      JP 2002-354122                      20021205

ABSTRACT:

Selenocysteine-containing proteins and peptides, including selenoprotein P, are claimed as antiinflammatory agents for treatment of IL-6 formation-related inflammatory diseases.

=> DIS L2 2 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L2 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:            2004:490735 CAPLUS  
DOCUMENT NUMBER:            141:47351  
TITLE:                      Novel agent for improving neurotransmission failure  
INVENTOR(S):                Kawamura, Ryoichi; Naruse, Takeshi;  
                             Hirashima, Masaki; Kaminaka, Kazuyoshi; Matsuda,  
                             Junichi; Maeda, Hiroaki; Noda, Mami; Wada, Keiji  
PATENT ASSIGNEE(S):        Juridical Foundation the Chemo-Sero-Therapeutic  
                             Research Institute, Japan  
SOURCE:                      PCT Int. Appl., 31 pp.  
                             CODEN: PIXXD2  
DOCUMENT TYPE:               Patent  
LANGUAGE:                    Japanese  
FAMILY ACC. NUM. COUNT:    1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004050114	A1	20040617	WO 2003-JP15227	20031128
W: US				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
JP 2004182616	A	20040702	JP 2002-348714	20021129
EP 1566181	A1	20050824	EP 2003-812336	20031128
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK				
US 2006211609	A1	20060921	US 2005-536963	20050531
PRIORITY APPLN. INFO.:			JP 2002-348714	A 20021129
			WO 2003-JP15227	W 20031128

ABSTRACT:

It is intended to provide a novel agent for improving neurotransmission failure. In a preferable case, an agent for improving neurotransmission failure which contains, as the major active ingredient(s), a selenocysteine-containing protein typified by selenoprotein P, a C-terminal peptide of this protein or such peptides. This agent is appropriate in improving neurotransmission failure diseases caused by various factors.

REFERENCE COUNT:            12            THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L2 3 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L2 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:            2002:888926 CAPLUS  
DOCUMENT NUMBER:            137:380908  
TITLE:                      Screening system for inhibitors of cell apoptosis and  
                             the use of the system for screening of selenocystine  
INVENTOR(S):                Hirashima, Masaki; Naruse, Takeshi; Maeda,

PATENT ASSIGNEE(S): Hiroaki; Nozaki, Chikateru; Goto, Takeshi; Akiyama, Katsuhiko; Hattori, Wataru  
Juridical Foundation the Chemo-Sero-Therapeutic Research Institute, Japan; Hisamitsu Pharmaceutical Co., Inc.  
SOURCE: PCT Int. Appl., 43 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092810	A1	20021121	WO 2002-JP4557	20020510
W: AU, CA, JP, US RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
EP 1386963	A1	20040204	EP 2002-724757	20020510
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1726649	A2	20061129	EP 2006-10000	20020510
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
US 2005143311	A1	20050630	US 2003-477101	20031110
PRIORITY APPLN. INFO.: JP 2001-141466 A 20010511 EP 2002-724757 A3 20020510 WO 2002-JP4557 W 20020510				

ABSTRACT:

This invention provides a system for screening of inhibitors of cell apoptosis. The effect of substances on the cell death in serum free medium containing albumin and fatty acid was used for screening inhibitor of apoptosis. In this system, the decrease of peroxidized fat content and increase of glutathione peroxidase activity were used as indicators for inhibition of apoptosis. Using the system provided in this invention, the 260-362 fragment of selenoprotein P was screened as low cytotoxic cell apoptosis inhibitor.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L2 4 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L2 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2002:888588 CAPLUS  
DOCUMENT NUMBER: 137:380034  
TITLE: Novel remedies for neurodegenerative disease  
INVENTOR(S): Hirashima, Masaki; Naruse, Takeshi; Maeda, Hiroaki; Nozaki, Chikateru; Goto, Takeshi; Akiyama, Katsuhiko; Fukushima, Hidenao  
PATENT ASSIGNEE(S): Juridical Foundation the Chemo-Sero-Therapeutic Research Institute, Japan; Hisamitsu Pharmaceutical Co., Inc.  
SOURCE: PCT Int. Appl., 31 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2002092121 A1 20021121 WO 2002-JP4558 20020510  
W: AU, CA, JP, US  
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,  
PT, SE, TR  
EP 1393740 A1 20040303 EP 2002-769564 20020510  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, FI, CY, TR  
US 2005143310 A1 20050630 US 2003-477216 20031110  
PRIORITY APPLN. INFO.: JP 2001-141462 A 20010511  
WO 2002-JP4558 W 20020510

ABSTRACT:

Remedies for neurodegenerative diseases which comprise selenoprotein P or C-terminal peptide(s) of this protein as the main active ingredient. These remedies are appropriately usable for neurodegenerative diseases showing motor ataxia as the major symptom.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> disp l2 ibib abs 5-6

THE ESTIMATED COST FOR THIS REQUEST IS 5.66 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L2 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:754241 CAPLUS  
DOCUMENT NUMBER: 137:273195  
TITLE: Novel drugs containing selenoprotein P for preventing/treating immune diseases  
INVENTOR(S): Hirashima, Masaki; Sasaki, Takumi; Naruse, Takeshi; Maeda, Hiroaki; Nozaki, Chikateru  
PATENT ASSIGNEE(S): Juridical Foundation the Chemo-Sero-Therapeutic Research Institute, Japan  
SOURCE: PCT Int. Appl., 26 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076493	A1	20021003	WO 2002-JP2645	20020320
W: AU, CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				

PRIORITY APPLN. INFO.: JP 2001-84049 A 20010323

AB Disclosed are novel preventives and remedies for immunopathic diseases which contain selenoprotein P and/or peptide(s) of this protein as the main component. These preventives and remedies are appropriately usable for autoimmune diseases typified by rheumatoid arthritis and multiple sclerosis and allergic diseases typified by bronchial asthma. A selenoprotein P fragment was isolated from human plasma, and its effect on collagen-induced arthritis in mouse was examined

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:754240 CAPLUS  
DOCUMENT NUMBER: 137:273220  
TITLE: Novel agents containing selenoprotein P for ameliorating motor disorder  
INVENTOR(S): Hirashima, Masaki; Sasaki, Takumi; Naruse, Takeshi; Maeda, Hiroaki; Nozaki, Chikateru



PATENT ASSIGNEE(S): Juridical Foundation the Chemo-Sero-Therapeutic  
Research Institute, Japan  
SOURCE: PCT Int. Appl., 27 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076492	A1	20021003	WO 2001-JP7525	20010831
W: AU, CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
CA 2441403	A1	20021003	CA 2001-2441403	20010831
EP 1374887	A1	20040102	EP 2001-961246	20010831
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
US 2005037954	A1	20050217	US 2003-472444	20030923
PRIORITY APPLN. INFO.:			JP 2001-84050	A 20010323
			WO 2001-JP7525	W 20010831

AB Disclosed are novel remedies for neurodegenerative diseases (in particular, agents for ameliorating motor disorder) which contain as the main component(s) selenoprotein P and/or peptide(s) of this protein. These remedies for neurodegenerative diseases (in particular, agents for ameliorating motor disorder) are appropriately usable particularly for diseases in association with depression in motor function. A selenoprotein P fragment was isolated from human plasma, and its effect on motor disorder in Klotho mouse was examined

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> E HIRASHIMA MASAKI/IN 25

E1	10	HIRASHIMA MAREHIKO/IN
E2	1	HIRASHIMA MASAOKI/IN
E3	17 -->	HIRASHIMA MASAKI/IN
E4	18	HIRASHIMA MASAO/IN
E5	1	HIRASHIMA MASAOTO/IN
E6	1	HIRASHIMA MASAYA/IN
E7	1	HIRASHIMA MASAYOSHI/IN
E8	1	HIRASHIMA MIKIHIRO/IN
E9	2	HIRASHIMA MINORU/IN
E10	12	HIRASHIMA MITSUOMI/IN
E11	1	HIRASHIMA MITSUYOSHI/IN
E12	1	HIRASHIMA NAME NOT TRANSLATED/IN
E13	18	HIRASHIMA NAOKI/IN
E14	7	HIRASHIMA NOBUCHIKA/IN
E15	13	HIRASHIMA NOBUHIRO/IN
E16	2	HIRASHIMA NOBUYUKI/IN
E17	5	HIRASHIMA NORIYUKI/IN
E18	1	HIRASHIMA OSAMU/IN
E19	1	HIRASHIMA RYOICHI/IN
E20	5	HIRASHIMA RYUSUKE/IN
E21	3	HIRASHIMA SACHIKO/IN
E22	1	HIRASHIMA SADAHIRO/IN
E23	1	HIRASHIMA SAIKICHI/IN
E24	1	HIRASHIMA SEKI/IN
E25	1	HIRASHIMA SHIGEO/IN

=> S (E3) AND (SELENOPROTEIN)

17 "HIRASHIMA MASAKI"/IN  
1089 SELENOPROTEIN

## 626 SELENOPROTEINS

## 1298 SELENOPROTEIN

(SELENOPROTEIN OR SELENOPROTEINS)

L3 12 ("HIRASHIMA MASAKI"/IN) AND (SELENOPROTEIN)

=&gt; DIS L3 1 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L3 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:1355995 CAPLUS

TITLE: Prophylactic or therapeutic agent for  
corneal/conjunctival diseaseINVENTOR(S): Watanabe, Masanao; Tsubota, Kazuo; Hirashima,  
Masaki; Nozaki, ChikateruPATENT ASSIGNEE(S): Kowa Company, Ltd., Japan; Juridical Foundation the  
Chemo-Sero-Therapeutic Research Institute

SOURCE: PCT Int. Appl., 20pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006137426	A1	20061228	WO 2006-JP312392	20060621
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.:

JP 2005-182597

A 20050622

ABSTRACT:

Disclosed is a novel composition for the treatment of a corneal/ conjunctival disease. A prophylactic or therapeutic agent for a corneal/conjunctival disease comprising selenoprotein P as an active ingredient, more specifically a prophylactic or therapeutic agent for a corneal/conjunctival disease such as dry eye, keratoconjunctivitis sicca, punctate superficial keratitis, corneal erosion or corneal ulcer comprising selenoprotein P as an active ingredient, particularly a prophylactic or therapeutic agent for a corneal/conjunctival disease such as dry eye, keratoconjunctivitis sicca, punctate superficial keratitis, corneal erosion or corneal ulcer accompanied by a corneal and conjunctival epithelial disorder.

REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=&gt; DIS L3 2 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L3 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:1038232 CAPLUS

DOCUMENT NUMBER: 142:18453

TITLE: Recombinant expression of selenocysteine-containing

proteins in animal cells: secretion of human selenoprotein P in milk of transgenic mouse with  $\beta$ -casein promoter

INVENTOR(S): Hosoe, Misa; Tokunaga, Tomoyuki; Furusawa, Ki; Takahashi, Kiyoya; Matsuda, Junichi; Hirashima, Masaki; Uenaka, Kazuyoshi; Maeda, Hiroaki

PATENT ASSIGNEE(S): The Chemo-Sero-Therapeutic Research Institute, Japan; National Institute of Agrobiological Resources NIAR; National Institute of Agro-Environmental Sciences

SOURCE: Jpn. Kokai Tokkyo Koho, 22 pp.  
CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004337090	A	20041202	JP 2003-138582	20030516
PRIORITY APPLN. INFO.:			JP 2003-138582	20030516

ABSTRACT:

A gene construct for recombinant expression of selenocysteine-containing proteins, and its use in production of selenoproteins in animal cells, in are disclosed. The expression unit contains a regulatory sequence specific for secretory organs, selenoprotein coding sequence, and a selenocysteine insertion sequence (SECIS) located in the 3'-UTR. Transcriptional control sequence of  $\beta$ -casein,  $\beta$ -lactoglobulin, or whey acidic protein for secretion in milk, regulatory sequence of blood proteins, or liver expressed proteins for serum secretion, and other for urinary or semen secretion, is used. Egg, embryo, ES cell, primordial germ cell (PGC), or somatic cell is transformed with the expression construct to obtain a transgenic animal cell, which can be transplanted into a mammal or a bird. In order to secrete into milk, human selenoprotein P cDNA was ligated to bovine  $\beta$ -casein gene promoter. The resulting expression unit was microinjected into a mouse fertilized egg. Up to 2.5  $\mu$ g/mL (83 times 30 ng/mL with prior method with CHO cell) of recombinant human selenoprotein P was obtained.

=> DIS L3 3 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L3 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:529749 CAPLUS

DOCUMENT NUMBER: 141:65101

TITLE: Selenocysteine-containing proteins and peptides as antiinflammatory agents

INVENTOR(S): Matsuyama, Reiko; Kawamura, Ryoichi; Sasaki, Takumi; Naruse, Takeshi; Hirashima, Masaki; Maeda, Hiroaki

PATENT ASSIGNEE(S): D.N.H. Chip Kenkyusho K. K., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 16 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004182683	A	20040702	JP 2002-354122	20021205
PRIORITY APPLN. INFO.:			JP 2002-354122	20021205

ABSTRACT:

Selenocysteine-containing proteins and peptides, including selenoprotein P, are claimed as antiinflammatory agents for treatment of IL-6 formation-related inflammatory diseases.

=> DIS L3 4 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L3 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:490735 CAPLUS

DOCUMENT NUMBER: 141:47351

TITLE: Novel agent for improving neurotransmission failure

INVENTOR(S): Kawamura, Ryoichi; Naruse, Takeshi; Hirashima, Masaki; Kaminaka, Kazuyoshi; Matsuda, Junichi; Maeda, Hiroaki; Noda, Mami; Wada, Keiji

PATENT ASSIGNEE(S): Juridical Foundation the Chemo-Sero-Therapeutic Research Institute, Japan

SOURCE: PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004050114	A1	20040617	WO 2003-JP15227	20031128
W: US				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
JP 2004182616	A	20040702	JP 2002-348714	20021129
EP 1566181	A1	20050824	EP 2003-812336	20031128
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK				
US 2006211609	A1	20060921	US 2005-536963	20050531
PRIORITY APPLN. INFO.:			JP 2002-348714	A 20021129
			WO 2003-JP15227	W 20031128

ABSTRACT:

It is intended to provide a novel agent for improving neurotransmission failure. In a preferable case, an agent for improving neurotransmission failure which contains, as the major active ingredient(s), a selenocysteine-containing protein typified by selenoprotein P, a C-terminal peptide of this protein or such peptides. This agent is appropriate in improving neurotransmission failure diseases caused by various factors.

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L3 5 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L3 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:154459 CAPLUS

DOCUMENT NUMBER: 138:193237

TITLE: Method of preparing peptide fragment having cell death inhibitory activity

INVENTOR(S): Kamei, Shintaro; Hamamoto, Takayoshi; Hirashima, Masaki; Maeda, Hiroaki; Takahashi, Kazuhiko

PATENT ASSIGNEE(S): Juridical Foundation the Chemo-Sero-Therapeutic Research Institute, Japan

SOURCE: PCT Int. Appl., 25 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003016347	A1	20030227	WO 2002-JP8042	20020807
W: AU, CA, JP, US				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
EP 1418182	A1	20040512	EP 2002-760561	20020807
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR, BG, CZ, EE, SK				
US 2004197852	A1	20041007	US 2004-486267	20040209
PRIORITY APPLN. INFO.:			JP 2001-242093	A 20010809
			WO 2002-JP8042	W 20020807

ABSTRACT:

To obtain a selenoprotein P fragment having a cell death inhibitory activity, full-length mols. are treated with various serine proteases and the results are evaluated based on electrophoresis and cell death inhibitory activity. Thus, an enzyme forming an active band assignable to a mol. weight of 35,000 or less is clarified by the electrophoresis and, as a result, a method of preparing the selenoprotein P fragment is established. This method of preparing a peptide fragment having a cell death inhibitory activity is usable in relieving, treating and preventing diseases caused by cell death, elevating the efficiency in producing a useful biol. substance in cultured cells, etc.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L3 6 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L3 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:68546 CAPLUS

DOCUMENT NUMBER: 138:131107

TITLE: Selenoprotein P and its peptide analogs for diagnosis and treatment of rheumatism

INVENTOR(S): Hirashima, Masaki; Sasaki, Takumi; Maeda, Hiroaki; Nozaki, Chikateru; Maruyama, Ikuo; Takahashi, Kazuhiko

PATENT ASSIGNEE(S): Chemo-Sero-Therapeutic Research Institute, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003026598	A	20030129	JP 2001-194617	20010627
PRIORITY APPLN. INFO.:			JP 2001-194617	20010627

ABSTRACT:

Selenoprotein P and its peptide analogs are claimed for prevention and treatment of rheumatism. Determination of blood or tissue selenoprotein P can also be used as a marker for diagnosis of chronic rheumatoid arthritis by using ELISA, RIA, Western blot, and other immunoassay.

=> DIS L3 7 IBIB IABS  
THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L3 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2002:888926 CAPLUS  
DOCUMENT NUMBER: 137:380908  
TITLE: Screening system for inhibitors of cell apoptosis and  
the use of the system for screening of selenocystine  
INVENTOR(S): Hirashima, Masaki; Naruse, Takeshi; Maeda,  
Hiroaki; Nozaki, Chikateru; Goto, Takeshi; Akiyama,  
Katsuhiko; Hattori, Wataru  
PATENT ASSIGNEE(S): Juridical Foundation the Chemo-Sero-Therapeutic  
Research Institute, Japan; Hisamitsu Pharmaceutical  
Co., Inc.  
SOURCE: PCT Int. Appl., 43 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092810	A1	20021121	WO 2002-JP4557	20020510
W: AU, CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
EP 1386963	A1	20040204	EP 2002-724757	20020510
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1726649	A2	20061129	EP 2006-10000	20020510
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
US 2005143311	A1	20050630	US 2003-477101	20031110
PRIORITY APPLN. INFO.:			JP 2001-141466	A 20010511
			EP 2002-724757	A3 20020510
			WO 2002-JP4557	W 20020510

ABSTRACT:  
This invention provides a system for screening of inhibitors of cell apoptosis.  
The effect of substances on the cell death in serum free medium containing albumin  
and fatty acid was used for screening inhibitor of apoptosis. In this system,  
the decrease of peroxidized fat content and increase of glutathione peroxidase  
activity were used as indicators for inhibition of apoptosis. Using the system  
provided in this invention, the 260-362 fragment of selenoprotein P  
was screened as low cytotoxic cell apoptosis inhibitor.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L3 8 IBIB IABS  
THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L3 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2002:888588 CAPLUS  
DOCUMENT NUMBER: 137:380034  
TITLE: Novel remedies for neurodegenerative disease  
INVENTOR(S): Hirashima, Masaki; Naruse, Takeshi; Maeda,  
Hiroaki; Nozaki, Chikateru; Goto, Takeshi; Akiyama,  
Katsuhiko; Fukushima, Hidenao

PATENT ASSIGNEE(S): Juridical Foundation the Chemo-Sero-Therapeutic Research Institute, Japan; Hisamitsu Pharmaceutical Co., Inc.  
 SOURCE: PCT Int. Appl., 31 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092121	A1	20021121	WO 2002-JP4558	20020510
W: AU, CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
EP 1393740	A1	20040303	EP 2002-769564	20020510
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
US 2005143310	A1	20050630	US 2003-477216	20031110
PRIORITY APPLN. INFO.:			JP 2001-141462	A 20010511
			WO 2002-JP4558	W 20020510

ABSTRACT:  
 Remedies for neurodegenerative diseases which comprise selenoprotein P or C-terminal peptide(s) of this protein as the main active ingredient. These remedies are appropriately usable for neurodegenerative diseases showing motor ataxia as the major symptom.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L3 9 IBIB IABS  
 THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS  
 DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L3 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2002:754241 CAPLUS  
 DOCUMENT NUMBER: 137:273195  
 TITLE: Novel drugs containing selenoprotein P for preventing/treating immune diseases  
 INVENTOR(S): Hirashima, Masaki; Sasaki, Takumi; Naruse, Takeshi; Maeda, Hiroaki; Nozaki, Chikateru  
 PATENT ASSIGNEE(S): Juridical Foundation the Chemo-Sero-Therapeutic Research Institute, Japan  
 SOURCE: PCT Int. Appl., 26 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076493	A1	20021003	WO 2002-JP2645	20020320
W: AU, CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
PRIORITY APPLN. INFO.:			JP 2001-84049	A 20010323

ABSTRACT:  
 Disclosed are novel preventives and remedies for immunopathic diseases which contain selenoprotein P and/or peptide(s) of this protein as the main component. These preventives and remedies are appropriately usable for autoimmune diseases typified by rheumatoid arthritis and multiple sclerosis and

allergic diseases typified by bronchial asthma. A selenoprotein P fragment was isolated from human plasma, and its effect on collagen-induced arthritis in mouse was examined

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L3 10 IBIB IABS  
THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L3 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2002:754240 CAPLUS  
DOCUMENT NUMBER: 137:273220  
TITLE: Novel agents containing selenoprotein P for ameliorating motor disorder  
INVENTOR(S): Hirashima, Masaki; Sasaki, Takumi; Naruse, Takeshi; Maeda, Hiroaki; Nozaki, Chikateru  
PATENT ASSIGNEE(S): Juridical Foundation the Chemo-Sero-Therapeutic Research Institute, Japan  
SOURCE: PCT Int. Appl., 27 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076492	A1	20021003	WO 2001-JP7525	20010831
W: AU, CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
CA 2441403	A1	20021003	CA 2001-2441403	20010831
EP 1374887	A1	20040102	EP 2001-961246	20010831
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
US 2005037954	A1	20050217	US 2003-472444	20030923
PRIORITY APPLN. INFO.:			JP 2001-84050	A 20010323
			WO 2001-JP7525	W 20010831

ABSTRACT:  
Disclosed are novel remedies for neurodegenerative diseases (in particular, agents for ameliorating motor disorder) which contain as the main component(s) \*\*\*selenoprotein\*\*\* P and/or peptide(s) of this protein. These remedies for neurodegenerative diseases (in particular, agents for ameliorating motor disorder) are appropriately usable particularly for diseases in association with depression in motor function. A selenoprotein P fragment was isolated from human plasma, and its effect on motor disorder in Klotho mouse was examined

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L3 11 IBIB IABS  
THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L3 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2002:147620 CAPLUS  
DOCUMENT NUMBER: 136:194250  
TITLE: Selenoprotein P and its peptide analogs as new inhibitors for ischemia-reperfusion injury



INVENTOR(S): Hirashima, Masaki; Maeda, Hiroaki; Nozaki,  
Tadahide  
PATENT ASSIGNEE(S): Chemo-Sero-Therapeutic Research Institute, Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.  
CODEN: JKXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002060346	A	20020226	JP 2001-54750	20010228
WO 2002067976	A1	20020906	WO 2001-JP7524	20010831

W: AU, CA, US

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,  
PT, SE, TR

PRIORITY APPLN. INFO.: JP 2000-148908 A 20000519  
JP 2000-174294 A 20000609  
JP 2001-54750 A 20010228

# ABSTRACT:

Selenoprotein P and its peptide analogs are claimed as new inhibitors for ischemia-reperfusion injury, including cerebral infarction, myocardial infarction, motor dysfunction from vascular injury, and other organ and tissue damage from organ transplants.

=> DIS.L3 12 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L3 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:368427 CAPLUS

DOCUMENT NUMBER: 133:16306

TITLE: Peptide fragments having cell death inhibitory activity

INVENTOR(S): Hirashima, Masaki; Maeda, Hiroaki; Nozaki,  
Chikateru

PATENT ASSIGNEE(S): Juridical Foundation the Chemo-Sero-Therapeutic  
Research Institute, Japan

SOURCE: PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000031131	A1	20000602	WO 1999-JP6322	19991112

W: AU, CA, JP, US

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,  
PT, SE

CA 2351558	A1	20000602	CA 1999-2351558	19991112
------------	----	----------	-----------------	----------

AU 2000011795	A	20000613	AU 2000-11795	19991112
---------------	---	----------	---------------	----------

EP 1132402	A1	20010912	EP 1999-972642	19991112
------------	----	----------	----------------	----------

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, FI

US 2005281808	A1	20051222	US 2005-185859	20050721
---------------	----	----------	----------------	----------

PRIORITY APPLN. INFO.: JP 1998-347863 A 19981119  
WO 1999-JP6322 W 19991112  
US 2001-856199 A3 20010518

# ABSTRACT:

Peptide fragment(s) having an activity of inhibiting cell death which contain the amino acid sequence consisting of 103 amino acid residues in the C-terminal side of selenoprotein P, an amino acid sequence derived from the above amino acid sequence by deletion, substitution or addition of one or several amino acids therein, or a partial sequence of either of the above amino acid sequences; remedies containing the above peptide fragment(s); antibodies against the above peptide fragment(s); and a method for screening a cell death inhibitory activity with the use of the above peptide fragment(s). Preferable examples of the above peptide fragment(s) are those containing the amino acid sequence(s) represented by SEQ ID NO:1 and/or 2 or partial sequences thereof. The cell death-inhibiting peptide fragments are useful for drug screening and for preventing and treating apoptosis-associated diseases such as AIDS, Parkinson's disease, Alzheimer's disease, atherosclerosis, myocardial infarction, cerebral infarction, organ transplant, reperfusion injury, etc.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> E KAMINAKA KAZUYOSHI/IN 25

E1	4	KAMINAKA KAZUSHIGE/IN
E2	1	KAMINAKA KAZUYA/IN
E3	6 -->	KAMINAKA KAZUYOSHI/IN
E4	1	KAMINAKA MAKOTO/IN
E5	29	KAMINAKA MANABU/IN
E6	1	KAMINAKA MASAO/IN
E7	1	KAMINAKA MIOJI/IN
E8	5	KAMINAKA MOTOFUMI/IN
E9	1	KAMINAKA NOBUYUKI/IN
E10	1	KAMINAKA NORIAKI/IN
E11	1	KAMINAKA SARA/IN
E12	1	KAMINAKA SHIGEYOSHI/IN
E13	1	KAMINAKA SHOJI/IN
E14	2	KAMINAKA TOSHIMITSU/IN
E15	2	KAMINAKA TOSHIYUKI/IN
E16	1	KAMINAKA YAMATO/IN
E17	1	KAMINAKA YOSHIMI/IN
E18	2	KAMINAKA YOSHINORI/IN
E19	19	KAMINAKAI HIROAKI/IN
E20	7	KAMINAKAI KAZUO/IN
E21	18	KAMINAMI SEIJI/IN
E22	1	KAMINAMI TAKASHI/IN
E23	21	KAMINAMI YASUO/IN
E24	1	KAMINAN MASAHIRO/IN
E25	5	KAMINAN TAKESHI/IN

=> S (E3) AND (SELENOPROTEIN)

6 "KAMINAKA KAZUYOSHI"/IN  
 1089 SELENOPROTEIN  
 626 SELENOPROTEINS  
 1298 SELENOPROTEIN  
 (SELENOPROTEIN OR SELENOPROTEINS)

L4 1 ("KAMINAKA KAZUYOSHI"/IN) AND (SELENOPROTEIN)

=> DIS L4 1 TI

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN  
 TI Novel agent for improving neurotransmission failure

=> E MATSUDA JUNICHI/IN 25

E1	8	MATSUDA JUJIRO/IN
E2	20	MATSUDA JUN/IN
E3	77 -->	MATSUDA JUNICHI/IN

E4	5	MATSUDA JUNICHIRO/IN
E5	1	MATSUDA JUNICHIROU/IN
E6	30	MATSUDA JUNJI/IN
E7	4	MATSUDA JUNKO/IN
E8	3	MATSUDA JUNYA/IN
E9	7	MATSUDA JUZO/IN
E10	4	MATSUDA JUZOU/IN
E11	17	MATSUDA KAMEMATSU/IN
E12	1	MATSUDA KAMETARO/IN
E13	4	MATSUDA KANAME/IN
E14	1	MATSUDA KANEAKI/IN
E15	13	MATSUDA KANEO/IN
E16	6	MATSUDA KANJI/IN
E17	2	MATSUDA KANKO/IN
E18	1	MATSUDA KANKOU/IN
E19	3	MATSUDA KANSHI/IN
E20	4	MATSUDA KAORI/IN
E21	44	MATSUDA KAORU/IN
E22	13	MATSUDA KATAYOSHI/IN
E23	3	MATSUDA KATSU/IN
E24	1	MATSUDA KATSUAKI/IN
E25	1	MATSUDA KATSUhide/IN

=> S (E3) AND (SELENOPROTEIN)

77 "MATSUDA JUNICHI"/IN

1089 SELENOPROTEIN

626 SELENOPROTEINS

1298 SELENOPROTEIN

(SELENOPROTEIN OR SELENOPROTEINS)

L5 2 ("MATSUDA JUNICHI"/IN) AND (SELENOPROTEIN)

=> DIS L5 1 TI

L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

TI Recombinant expression of selenocysteine-containing proteins in animal cells: secretion of human selenoprotein P in milk of transgenic mouse with  $\beta$ -casein promoter

=> DIS L5 2 TI

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

TI Novel agent for improving neurotransmission failure

=> E MAEDA HIROAKI/IN 25

E1	2	MAEDA HIKARI/IN
E2	2	MAEDA HIKARU/IN
E3	80 -->	MAEDA HIROAKI/IN
E4	3	MAEDA HIROBUMI/IN
E5	25	MAEDA HIROE/IN
E6	13	MAEDA HIROFUMI/IN
E7	1	MAEDA HIROHISA/IN
E8	7	MAEDA HIROHITO/IN
E9	1	MAEDA HIROHUMI/IN
E10	2	MAEDA HIROICHI/IN
E11	11	MAEDA HIROJI/IN
E12	12	MAEDA HIROKAGE/IN
E13	2	MAEDA HIROKATSU/IN
E14	33	MAEDA HIROKAZU/IN
E15	40	MAEDA HIROKI/IN
E16	2	MAEDA HIROKICHI/IN
E17	31	MAEDA HIROKO/IN
E18	2	MAEDA HIROKUNI/IN

E19 1 MAEDA HIROMASA/IN  
 E20 57 MAEDA HIROMI/IN  
 E21 4 MAEDA HIROMITSU/IN  
 E22 5 MAEDA HIROMU/IN  
 E23 1 MAEDA HIRONAGA/IN  
 E24 6 MAEDA HIRONARI/IN  
 E25 9 MAEDA HIRONOBU/IN

=> S (E3) AND (SELENOPROTEIN)

80 "MAEDA HIROAKI"/IN  
 1089 SELENOPROTEIN  
 626 SELENOPROTEINS  
 1298 SELENOPROTEIN  
 (SELENOPROTEIN OR SELENOPROTEINS)

L6 11 ("MAEDA HIROAKI"/IN) AND (SELENOPROTEIN)

=> DIS L6 1 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L6 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:1038232 CAPLUS

DOCUMENT NUMBER: 142:18453

TITLE: Recombinant expression of selenocysteine-containing proteins in animal cells: secretion of human selenoprotein P in milk of transgenic mouse with  $\beta$ -casein promoter

INVENTOR(S): Hosoe, Misa; Tokunaga, Tomoyuki; Furusawa, Ki; Takahashi, Kiyoya; Matsuda, Junichi; Hirashima, Masaki; Uenaka, Kazuyoshi; Maeda, Hiroaki

PATENT ASSIGNEE(S): The Chemo-Sero-Therapeutic Research Institute, Japan; National Institute of Agrobiological Resources NIAR; National Institute of Agro-Environmental Sciences

SOURCE: Jpn. Kokai Tokkyo Koho, 22 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004337090	A	20041202	JP 2003-138582	20030516
PRIORITY APPLN. INFO.:			JP 2003-138582	20030516

ABSTRACT:

A gene construct for recombinant expression of selenocysteine-containing proteins, and its use in production of selenoproteins in animal cells, in are disclosed. The expression unit contains a regulatory sequence specific for secretory organs, selenoprotein coding sequence, and a selenocysteine insertion sequence (SECIS) located in the 3'-UTR. Transcriptional control sequence of  $\beta$ -casein,  $\beta$ -lactoglobulin, or whey acidic protein for secretion in milk, regulatory sequence of blood proteins, or liver expressed proteins for serum secretion, and other for urinary or semen secretion, is used. Egg, embryo, ES cell, primordial germ cell (PGC), or somatic cell is transformed with the expression construct to obtain a transgenic animal cell, which can be transplanted into a mammal or a bird. In order to secrete into milk, human selenoprotein P cDNA was ligated to bovine  $\beta$ -casein gene promoter. The resulting expression unit was microinjected into a mouse fertilized egg. Up to 2.5  $\mu$ g/mL (83 times 30 ng/mL with prior method with CHO cell) of recombinant human selenoprotein P was obtained.

=> DIS L6 2 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L6 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2004:529749 CAPLUS  
DOCUMENT NUMBER: 141:65101  
TITLE: Selenocysteine-containing proteins and peptides as  
antiinflammatory agents  
INVENTOR(S): Matsuyama, Reiko; Kawamura, Ryoichi; Sasaki, Takumi;  
Naruse, Takeshi; Hirashima, Masaki; Maeda,  
Hiroaki  
PATENT ASSIGNEE(S): D.N.H. Chip Kenkyusho K. K., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 16 pp.  
CODEN: JKXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004182683	A	20040702	JP 2002-354122	20021205
PRIORITY APPLN. INFO.:			JP 2002-354122	20021205

ABSTRACT:  
Selenocysteine-containing proteins and peptides, including selenoprotein  
P, are claimed as antiinflammatory agents for treatment of IL-6  
formation-related inflammatory diseases.

=> DIS L6 3 IBIB IABS  
THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L6 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2004:490735 CAPLUS  
DOCUMENT NUMBER: 141:47351  
TITLE: Novel agent for improving neurotransmission failure  
INVENTOR(S): Kawamura, Ryoichi; Naruse, Takeshi; Hirashima, Masaki;  
Kaminaka, Kazuyoshi; Matsuda, Junichi; Maeda,  
Hiroaki; Noda, Mami; Wada, Keiji  
PATENT ASSIGNEE(S): Juridical Foundation the Chemo-Sero-Therapeutic  
Research Institute, Japan  
SOURCE: PCT Int. Appl., 31 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004050114	A1	20040617	WO 2003-JP15227	20031128
W: US				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
JP 2004182616	A	20040702	JP 2002-348714	20021129
EP 1566181	A1	20050824	EP 2003-812336	20031128
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK				
US 2006211609	A1	20060921	US 2005-536963	20050531
PRIORITY APPLN. INFO.:			JP 2002-348714	A 20021129
			WO 2003-JP15227	W 20031128

ABSTRACT:

It is intended to provide a novel agent for improving neurotransmission failure. In a preferable case, an agent for improving neurotransmission failure which contains, as the major active ingredient(s), a selenocysteine-containing protein typified by selenoprotein P, a C-terminal peptide of this protein or such peptides. This agent is appropriate in improving neurotransmission failure diseases caused by various factors.

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L6 4 IBIB IABS  
THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L6 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2003:154459 CAPLUS  
DOCUMENT NUMBER: 138:193237  
TITLE: Method of preparing peptide fragment having cell death inhibitory activity  
INVENTOR(S): Kamei, Shintaro; Hamamoto, Takayoshi; Hirashima, Masaki; Maeda, Hiroaki; Takahashi, Kazuhiko  
PATENT ASSIGNEE(S): Juridical Foundation the Chemo-Sero-Therapeutic Research Institute, Japan  
SOURCE: PCT Int. Appl., 25 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003016347	A1	20030227	WO 2002-JP8042	20020807
W: AU, CA, JP, US				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
EP 1418182	A1	20040512	EP 2002-760561	20020807
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR, BG, CZ, EE, SK				
US 2004197852	A1	20041007	US 2004-486267	20040209
PRIORITY APPLN. INFO.:			JP 2001-242093	A 20010809
			WO 2002-JP8042	W 20020807

ABSTRACT:  
To obtain a selenoprotein P fragment having a cell death inhibitory activity, full-length mols. are treated with various serine proteases and the results are evaluated based on electrophoresis and cell death inhibitory activity. Thus, an enzyme forming an active band assignable to a mol. weight of 35,000 or less is clarified by the electrophoresis and, as a result, a method of preparing the selenoprotein P fragment is established. This method of preparing a peptide fragment having a cell death inhibitory activity is usable in relieving, treating and preventing diseases caused by cell death, elevating the efficiency in producing a useful biol. substance in cultured cells, etc.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L6 5 IBIB IABS  
THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L6 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2003:68546 CAPLUS

DOCUMENT NUMBER: 138:131107  
 TITLE: Selenoprotein P and its peptide analogs for diagnosis and treatment of rheumatism  
 INVENTOR(S): Hirashima, Masaki; Sasaki, Takumi; Maeda, Hiroaki; Nozaki, Chikateru; Maruyama, Ikuo; Takahashi, Kazuhiko  
 PATENT ASSIGNEE(S): Chemo-Sero-Therapeutic Research Institute, Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003026598	A	20030129	JP 2001-194617	20010627
PRIORITY APPLN. INFO.:			JP 2001-194617	20010627

ABSTRACT:

Selenoprotein P and its peptide analogs are claimed for prevention and treatment of rheumatism. Determination of blood or tissue selenoprotein P can also be used as a marker for diagnosis of chronic rheumatoid arthritis by using ELISA, RIA, Western blot, and other immunoassay.

=> DIS L6 6 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS  
 DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L6 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:888926 CAPLUS  
 DOCUMENT NUMBER: 137:380908  
 TITLE: Screening system for inhibitors of cell apoptosis and the use of the system for screening of selenocystine  
 INVENTOR(S): Hirashima, Masaki; Naruse, Takeshi; Maeda, Hiroaki; Nozaki, Chikateru; Goto, Takeshi; Akiyama, Katsuhiko; Hattori, Wataru  
 PATENT ASSIGNEE(S): Juridical Foundation the Chemo-Sero-Therapeutic Research Institute, Japan; Hisamitsu Pharmaceutical Co., Inc.  
 SOURCE: PCT Int. Appl., 43 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092810	A1	20021121	WO 2002-JP4557	20020510
W: AU, CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
EP 1386963	A1	20040204	EP 2002-724757	20020510
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1726649	A2	20061129	EP 2006-10000	20020510
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
US 2005143311	A1	20050630	US 2003-477101	20031110
PRIORITY APPLN. INFO.:			JP 2001-141466	A 20010511
			EP 2002-724757	A3 20020510
			WO 2002-JP4557	W 20020510

ABSTRACT:

This invention provides a system for screening of inhibitors of cell apoptosis. The effect of substances on the cell death in serum free medium containing albumin and fatty acid was used for screening inhibitor of apoptosis. In this system, the decrease of peroxidized fat content and increase of glutathione peroxidase activity were used as indicators for inhibition of apoptosis. Using the system provided in this invention, the 260-362 fragment of selenoprotein P was screened as low cytotoxic cell apoptosis inhibitor.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L6 7 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L6 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:888588 CAPLUS

DOCUMENT NUMBER: 137:380034

TITLE: Novel remedies for neurodegenerative disease

INVENTOR(S): Hirashima, Masaki; Naruse, Takeshi; Maeda, Hiroaki; Nozaki, Chikateru; Goto, Takeshi; Akiyama, Katsuhiko; Fukushima, Hidenao

PATENT ASSIGNEE(S): Juridical Foundation the Chemo-Sero-Therapeutic Research Institute, Japan; Hisamitsu Pharmaceutical Co., Inc.

SOURCE: PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092121	A1	20021121	WO 2002-JP4558	20020510
W: AU, CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
EP 1393740	A1	20040303	EP 2002-769564	20020510
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
US 2005143310	A1	20050630	US 2003-477216	20031110
PRIORITY APPLN. INFO.:			JP 2001-141462	A 20010511
			WO 2002-JP4558	W 20020510

ABSTRACT:

Remedies for neurodegenerative diseases which comprise selenoprotein P or C-terminal peptide(s) of this protein as the main active ingredient. These remedies are appropriately usable for neurodegenerative diseases showing motor ataxia as the major symptom.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L6 8 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L6 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:754241 CAPLUS

DOCUMENT NUMBER: 137:273195

TITLE: Novel drugs containing selenoprotein P for



INVENTOR(S): preventing/treating immune diseases  
Hirashima, Masaki; Sasaki, Takumi; Naruse, Takeshi;  
Maeda, Hiroaki; Nozaki, Chikateru  
PATENT ASSIGNEE(S): Juridical Foundation the Chemo-Sero-Therapeutic  
Research Institute, Japan  
SOURCE: PCT Int. Appl., 26 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076493	A1	20021003	WO 2002-JP2645	20020320
W: AU, CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				

PRIORITY APPLN. INFO.: JP 2001-84049 A 20010323

ABSTRACT:

Disclosed are novel preventives and remedies for immunopathic diseases which contain selenoprotein P and/or peptide(s) of this protein as the main component. These preventives and remedies are appropriately usable for autoimmune diseases typified by rheumatoid arthritis and multiple sclerosis and allergic diseases typified by bronchial asthma. A selenoprotein P fragment was isolated from human plasma, and its effect on collagen-induced arthritis in mouse was examined

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L6 9 IBIB IABS  
THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L6 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:754240 CAPLUS  
DOCUMENT NUMBER: 137:273220  
TITLE: Novel agents containing selenoprotein P for ameliorating motor disorder  
INVENTOR(S): Hirashima, Masaki; Sasaki, Takumi; Naruse, Takeshi; Maeda, Hiroaki; Nozaki, Chikateru  
PATENT ASSIGNEE(S): Juridical Foundation the Chemo-Sero-Therapeutic Research Institute, Japan  
SOURCE: PCT Int. Appl., 27 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076492	A1	20021003	WO 2001-JP7525	20010831
W: AU, CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
CA 2441403	A1	20021003	CA 2001-2441403	20010831
EP 1374887	A1	20040102	EP 2001-961246	20010831
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
US 2005037954	A1	20050217	US 2003-472444	20030923
PRIORITY APPLN. INFO.:			JP 2001-84050	A 20010323

## ABSTRACT:

Disclosed are novel remedies for neurodegenerative diseases (in particular, agents for ameliorating motor disorder) which contain as the main component(s) \*\*\*selenoprotein\*\*\* P and/or peptide(s) of this protein. These remedies for neurodegenerative diseases (in particular, agents for ameliorating motor disorder) are appropriately usable particularly for diseases in association with depression in motor function. A selenoprotein P fragment was isolated from human plasma, and its effect on motor disorder in Klotho mouse was examined

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> DIS L6 10 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L6 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:147620 CAPLUS

DOCUMENT NUMBER: 136:194250

TITLE: Selenoprotein P and its peptide analogs as new inhibitors for ischemia-reperfusion injury

INVENTOR(S): Hirashima, Masaki; Maeda, Hiroaki; Nozaki, Tadahide

PATENT ASSIGNEE(S): Chemo-Sero-Therapeutic Research Institute, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002060346	A	20020226	JP 2001-54750	20010228
WO 2002067976	A1	20020906	WO 2001-JP7524	20010831

W: AU, CA, US

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR

PRIORITY APPLN. INFO.:	JP 2000-148908	A	20000519
	JP 2000-174294	A	20000609
	JP 2001-54750	A	20010228

## ABSTRACT:

Selenoprotein P and its peptide analogs are claimed as new inhibitors for ischemia-reperfusion injury, including cerebral infarction, myocardial infarction, motor dysfunction from vascular injury, and other organ and tissue damage from organ transplants.

=> DIS L6 11 IBIB IABS

THE ESTIMATED COST FOR THIS REQUEST IS 2.83 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L6 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:368427 CAPLUS

DOCUMENT NUMBER: 133:16306

TITLE: Peptide fragments having cell death inhibitory activity

INVENTOR(S): Hirashima, Masaki; Maeda, Hiroaki; Nozaki, Chikateru

PATENT ASSIGNEE(S): Juridical Foundation the Chemo-Sero-Therapeutic

SOURCE: Research Institute, Japan  
PCT Int. Appl., 56 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1.  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000031131	A1	20000602	WO 1999-JP6322	19991112
W: AU, CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2351558	A1	20000602	CA 1999-2351558	19991112
AU 2000011795	A	20000613	AU 2000-11795	19991112
EP 1132402	A1	20010912	EP 1999-972642	19991112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 2005281808	A1	20051222	US 2005-185859	20050721
PRIORITY APPLN. INFO.:			JP 1998-347863	A 19981119
			WO 1999-JP6322	W 19991112
			US 2001-856199	A3 20010518

# ABSTRACT:

Peptide fragment(s) having an activity of inhibiting cell death which contain the amino acid sequence consisting of 103 amino acid residues in the C-terminal side of selenoprotein P, an amino acid sequence derived from the above amino acid sequence by deletion, substitution or addition of one or several amino acids therein, or a partial sequence of either of the above amino acid sequences; remedies containing the above peptide fragment(s); antibodies against the above peptide fragment(s); and a method for screening a cell death inhibitory activity with the use of the above peptide fragment(s). Preferable examples of the above peptide fragment(s) are those containing the amino acid sequence(s) represented by SEQ ID NO:1 and/or 2 or partial sequences thereof. The cell death-inhibiting peptide fragments are useful for drug screening and for preventing and treating apoptosis-associated diseases such as AIDS, Parkinson's disease, Alzheimer's disease, atherosclerosis, myocardial infarction, cerebral infarction, organ transplant, reperfusion injury, etc.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> E NODA MAMI/IN 25

E1	1	NODA LEIGH TAKEO/IN
E2	39	NODA MAKOTO/IN
E3	1 -->	NODA MAMI/IN
E4	2	NODA MANABU/IN
E5	9	NODA MANDA/IN
E6	1	NODA MAREKAZU/IN
E7	30	NODA MARIKO/IN
E8	44	NODA MASA AKI/IN
E9	4	NODA MASAFUMI/IN
E10	45	NODA MASAHARU/IN
E11	6	NODA MASAHIKO/IN
E12	63	NODA MASAHIRO/IN
E13	1	NODA MASAJI/IN
E14	13	NODA MASAJIRO/IN
E15	1	NODA MASAKATSU/IN
E16	2	NODA MASAKAZU/IN
E17	30	NODA MASAKI/IN
E18	3	NODA MASAKUNI/IN
E19	20	NODA MASAMI/IN
E20	36	NODA MASA NORI/IN

E21	5	NODA MASAO/IN
E22	1	NODA MASAOKI/IN
E23	10	NODA MASARU/IN
E24	20	NODA MASASHI/IN
E25	3	NODA MASATAKA/IN

=> S (E3) AND (SELENOPROTEIN)

1	"NODA MAMI"/IN
1089	SELENOPROTEIN
626	SELENOPROTEINS
1298	SELENOPROTEIN

(SELENOPROTEIN OR SELENOPROTEINS)

L7 1 ("NODA MAMI"/IN) AND (SELENOPROTEIN)

=> DIS L7 1 TI

L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN  
 TI Novel agent for improving neurotransmission failure

=> E WADA KEIJI/IN 25

E1	21	WADA KEIICHIRO/IN
E2	1	WADA KEIICHIROU/IN
E3	55	--> WADA KEIJI/IN
E4	2	WADA KEIKI/IN
E5	4	WADA KEIKO/IN
E6	17	WADA KEISHI/IN
E7	1	WADA KEISHIRO/IN
E8	54	WADA KEISUKE/IN
E9	1	WADA KEITARO/IN
E10	2	WADA KEIZO/IN
E11	1	WADA KEIZUKE/IN
E12	1	WADA KEJI/IN
E13	2	WADA KEN/IN
E14	82	WADA KENICHI/IN
E15	183	WADA KENJI/IN
E16	1	WADA KENNETH R/IN
E17	1	WADA KENNOSUKE/IN
E18	2	WADA KENSHI/IN
E19	2	WADA KENSUKE/IN
E20	2	WADA KENTA/IN
E21	2	WADA KENTARO/IN
E22	19	WADA KENYA/IN
E23	5	WADA KENZO/IN
E24	1	WADA KICHIRO/IN
E25	1	WADA KIICHIRO/IN

=> S (E3) AND (SELENOPROTEIN)

55	"WADA KEIJI"/IN
1089	SELENOPROTEIN
626	SELENOPROTEINS
1298	SELENOPROTEIN

(SELENOPROTEIN OR SELENOPROTEINS)

L8 1 ("WADA KEIJI"/IN) AND (SELENOPROTEIN)

=> DIS L8 1 TI

L8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN  
 TI Novel agent for improving neurotransmission failure

=>